Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All studies

Bezuclastinib + Sunitinib

Peak

Cogent Biosciences · Phase 3 · Recruiting · Enrollment 482

NCT05208047

Catalyst Primary completion. 09.30.2025. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Catalyst FDA PDUFA target action date (GIST, with sunitinib). 11.30.2026. Company-stated goal date, not a promise of action.

ArmReported safety
Bezuclastinib 600 mg + sunitinib 37.5 mggrade 3 or higher ALT/AST increased: 10.8%, data cutoff 09.30.2025discontinued for treatment-related adverse events: 7.4%, data cutoff 09.30.2025
Sunitinib 37.5 mg continuousgrade 3 or higher ALT/AST increased: 1.4%, data cutoff 09.30.2025discontinued for treatment-related adverse events: 3.8%, data cutoff 09.30.2025

A count stays a count. This page does not turn a count into a percent.